Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency (STEP-OTC)

T

Translate Bio

Status and phase

Withdrawn
Phase 2
Phase 1

Conditions

Ornithine Transcarbamylase Deficiency

Treatments

Other: Placebo
Biological: MRT5201

Study type

Interventional

Funder types

Industry

Identifiers

NCT03767270
MRT5201-101
2018-004095-35 (EudraCT Number)

Details and patient eligibility

About

This Phase 1/2, first-in-human study will evaluate the safety and tolerability of single escalating doses of MRT5201 administered intravenously to subjects with OTC Deficiency (OTCD). This study will also evaluate the effect of a single dose of MRT5201 on metabolic markers of OTCD and ureagenesis; and determine an acceptable dosing interval of MRT5201.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have a documented diagnosis of OTCD.
  • Documented history of ≥1 symptomatic hyperammonemia event with ammonia ≥100 µmol/L

Subject's OTCD is stable as evidenced by meeting the following criteria:

  • Ammonia level <175 µmol/L during the Screening Period and at Baseline (Day -1)
  • No clinical symptoms of hyperammonemia during the Screening Period and at Baseline (Day -1)
  • If using nitrogen scavenger therapy, must be on a stable regimen for ≥28 days prior to signing informed consent
  • Subject has maintained a stable protein restricted diet (which may or may not include medical foods) and/or amino acid supplementation with no changes in calorie or protein goals and no changes in medical food and/or amino acid supplementation for ≥ 28 days prior to signing informed consent.

Exclusion criteria

Any laboratory abnormality that may put the subject at increased risk by participating in this study.

Have any significant concurrent or past medical condition that would represent an unacceptable risk to the subject or might jeopardize the collection of high-quality data from the study. These include but are not limited to:

  • History of liver transplant, including hepatocyte therapy/transplant
  • History of liver disease
  • Positive viral serology test results for HIV type 1 or 2 antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody
  • Type I or Type II diabetes that is poorly controlled, in the opinion of the Investigator
  • Poorly controlled hypertension (defined as systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 90 mm Hg)
  • Use of anticoagulants or platelet inhibitors, including but not limited to heparin and non-steroidal anti-inflammatory drugs (NSAIDS). Acetaminophen is permitted
  • Participation in previous clinical studies evaluating investigational OTCD therapies directed at expressing functional OTC protein (eg, OTC gene therapy studies, other mRNA replacement therapy) that has led to the presence of anti-OTC antibodies.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Quadruple Blind

0 participants in 2 patient groups, including a placebo group

MRT5201
Experimental group
Description:
Single Ascending Low, Mid, and High doses of MRT5201
Treatment:
Biological: MRT5201
Placebo
Placebo Comparator group
Description:
Placebo comparator using 5% dextrose in water at the same administration rate as study drug.
Treatment:
Other: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems